Antimicrobial Therapeutics Market Size, Share, and Analysis, By Drug Class (Antibacterial, Antivirals, Antifungal, and Antiparasitic), By Route of Administration (Oral, Tropic, Injectable, and Others), By Disease Indication (Respiratory Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Central Nervous System Infections, and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
Antimicrobial Therapeutics Market Size, Share, and Analysis, By Drug Class (Antibacterial, Antivirals, Antifungal, and Antiparasitic), By Route of Administration (Oral, Tropic, Injectable, and Others), By Disease Indication (Respiratory Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Central Nervous System Infections, and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
PRODUCT OVERVIEW
Antimicrobial Therapeutics Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 5.8% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 88.6 billion and is projected to reach USD 164.5 billion by the completion of 2034.
Antimicrobial therapies refer to a group of medicines that are used to battle a variety of microbial infections, such as bacteria, viruses, fungi, and parasites. These therapies are designed to prevent microbial development that causes the disease, thus reducing symptoms and promoting recovery. Antibiotics are the keystone of antimicrobial therapy as it targets bacterial infections by either eradicating the bacteria or inhibiting their growth. In addition, antimicrobial therapeutics also include antiviral drugs, along with antifungal medications and antiparasitic treatments. Moreover, research is being done to develop new antimicrobial medicines and improve current therapies to surpass microbial adaptation. Consequently, maintaining the effectiveness of these treatments and preventing antimicrobial resistance requires careful adherence to recommended regimens and the careful use of antibiotics.
MARKET HIGHLIGHTS
Antimicrobial therapeutics market is projected to reach USD 164.5 billion over the forecast period, owing to the rising prevalence of infectious diseases, along with the mounting challenge of antimicrobial resistance, which increases the demand for new treatments. Additionally, innovations in technology and healthcare infrastructure across emerging markets are contributing to the growth of the antimicrobial therapeutic market. The COVID-19 pandemic has further highlighted the importance of antimicrobial medicines and encouraged high investment in R&D activities. Moreover, industry players are frequently using strategic collaborations and acquisitions to strengthen their market positions. Thus, the antimicrobial therapeutics market will experience sustained growth due to the escalating burden of infectious diseases and the need to address antimicrobial resistance.
Antimicrobial Therapeutics Market Segments:
Growth Drivers
Growing Prevalence of Infectious Diseases to Present Growth Opportunities for the Antimicrobial Therapeutic Industry
Advancements in Technology Will Help in the Adoption of Therapies
Restraint
Antimicrobial Resistance May Prevent Growth in the Market
Key Players
PRODUCT OVERVIEW
Antimicrobial Therapeutics Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 5.8% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 88.6 billion and is projected to reach USD 164.5 billion by the completion of 2034.
Antimicrobial therapies refer to a group of medicines that are used to battle a variety of microbial infections, such as bacteria, viruses, fungi, and parasites. These therapies are designed to prevent microbial development that causes the disease, thus reducing symptoms and promoting recovery. Antibiotics are the keystone of antimicrobial therapy as it targets bacterial infections by either eradicating the bacteria or inhibiting their growth. In addition, antimicrobial therapeutics also include antiviral drugs, along with antifungal medications and antiparasitic treatments. Moreover, research is being done to develop new antimicrobial medicines and improve current therapies to surpass microbial adaptation. Consequently, maintaining the effectiveness of these treatments and preventing antimicrobial resistance requires careful adherence to recommended regimens and the careful use of antibiotics.
MARKET HIGHLIGHTS
Antimicrobial therapeutics market is projected to reach USD 164.5 billion over the forecast period, owing to the rising prevalence of infectious diseases, along with the mounting challenge of antimicrobial resistance, which increases the demand for new treatments. Additionally, innovations in technology and healthcare infrastructure across emerging markets are contributing to the growth of the antimicrobial therapeutic market. The COVID-19 pandemic has further highlighted the importance of antimicrobial medicines and encouraged high investment in R&D activities. Moreover, industry players are frequently using strategic collaborations and acquisitions to strengthen their market positions. Thus, the antimicrobial therapeutics market will experience sustained growth due to the escalating burden of infectious diseases and the need to address antimicrobial resistance.
Antimicrobial Therapeutics Market Segments:
- By Drug Class
- Antibacterial
- Antivirals
- Antifungal
- Antiparasitic
- By Route of Administration
- Oral
- Tropic
- Injectable
- Others
- By Disease Indication
- Respiratory Infections
- Urinary Tract Infections
- Skin and Soft Tissue Infections
- Sexually Transmitted Infections
- Gastrointestinal Infections
- Central Nervous System Infections
- Others
Growth Drivers
Growing Prevalence of Infectious Diseases to Present Growth Opportunities for the Antimicrobial Therapeutic Industry
Advancements in Technology Will Help in the Adoption of Therapies
Restraint
Antimicrobial Resistance May Prevent Growth in the Market
Key Players
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- Johnson & Johnson
- Novartis International AG
- Sanofi S.A.
- Roche Holding AG
- AstraZeneca PLC
- Bayer AG
- AbbVie Inc.
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Astellas Pharma Inc.
- Gilead Sciences, Inc.
- Boehringer Ingelheim GmbH
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
1. EXECUTIVE SUMMARY
1.1.Regional Market Share
1.2. Business Trends
1.3.Antimicrobial Therapeutics Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2.Public Sources
2.6.Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1. Market Definition
3.2.Antimicrobial Therapeutics Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. ANTIMICROBIAL THERAPEUTICS MARKET – INDUSTRY INSIGHTS
4.1.Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7.MARKET DYNAMICS
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. RISK ANALYSIS
9. MARKET ANALYSIS
9.1. Porter's Five Forces
9.2.PEST Analysis
9.2.1. Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological
10. ANTIMICROBIAL THERAPEUTICS MARKET
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11.ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Drug Class
11.3.1.1. Antibacterial
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2.Market Share (%) 2024-2034F
11.3.1.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Antivirals
11.3.1.2.1.By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Antifungal
11.3.1.3.1.By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.4.Antiparasitic
11.3.1.4.1.By Value (USD Million) 2024-2034F
11.3.1.4.2. Market Share (%) 2024-2034F
11.3.1.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1.Oral
11.3.2.1.1.By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Tropic
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2.Market Share (%) 2024-2034F
11.3.2.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Injectable
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2.Market Share (%) 2024-2034F
11.3.2.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.4. Others
11.3.2.4.1. By Value (USD Million) 2024-2034F
11.3.2.4.2.Market Share (%) 2024-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3. By Disease Indication
11.3.3.1.Respiratory Infections
11.3.3.1.1.By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Urinary Tract Infections
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2.Market Share (%) 2024-2034F
11.3.3.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Skin and Soft Tissue Infections
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2.Market Share (%) 2024-2034F
11.3.3.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Sexually Transmitted Infections
11.3.3.4.1. By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Gastrointestinal Infections
11.3.3.5.1. By Value (USD Million) 2024-2034F
11.3.3.5.2.Market Share (%) 2024-2034F
11.3.3.5.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.6. Central Nervous System Infections
11.3.3.6.1. By Value (USD Million) 2024-2034F
11.3.3.6.2.Market Share (%) 2024-2034F
11.3.3.6.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.7. Others
11.3.3.7.1. By Value (USD Million) 2024-2034F
11.3.3.7.2.Market Share (%) 2024-2034F
11.3.3.7.3.Y-o-Y Growth (%) 2024-2034F
12. NORTH AMERICA ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Class
12.3.2.By Route of Administration
12.3.3.By Disease Indication
12.4. Country
12.4.1. United States
12.4.2.Canada
13. EUROPE ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Class
13.3.2.By Route of Administration
13.3.3.By Disease Indication
13.4. Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4. Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. ASIA-PACIFIC ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Class
14.3.2.By Route of Administration
14.3.3.By Disease Indication
14.4. Country
14.4.1. India
14.4.2.China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. MIDDLE EAST AND AFRICA ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Class
15.3.2.By Route of Administration
15.3.3.By Disease Indication
15.4. Country
15.4.1. Israel
15.4.2.GCC
15.4.3.North Africa
15.4.4. South Africa
15.4.5.Rest of Middle East and Africa
16. LATIN AMERICA ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Class
16.3.2.By Route of Administration
16.3.3.By Disease Indication
16.4. Country
16.4.1. Mexico
16.4.2.Brazil
16.4.3.Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1. Company market share, 2023
17.2.Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1. Pfizer Inc.
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2.Merck & Co., Inc.
18.3.GlaxoSmithKline plc (GSK)
18.4.Johnson & Johnson
18.5.Novartis International AG
18.6.Sanofi S.A.
18.7.Roche Holding AG
18.8.AstraZeneca PLC
18.9.Bayer AG
18.10.AbbVie Inc.
18.11. Bristol Myers Squibb Company
18.12.Eli Lilly and Company
18.13.Astellas Pharma Inc.
18.14.Gilead Sciences, Inc.
18.15.Boehringer Ingelheim GmbH
18.16.Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
1.1.Regional Market Share
1.2. Business Trends
1.3.Antimicrobial Therapeutics Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2.Public Sources
2.6.Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1. Market Definition
3.2.Antimicrobial Therapeutics Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. ANTIMICROBIAL THERAPEUTICS MARKET – INDUSTRY INSIGHTS
4.1.Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7.MARKET DYNAMICS
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. RISK ANALYSIS
9. MARKET ANALYSIS
9.1. Porter's Five Forces
9.2.PEST Analysis
9.2.1. Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological
10. ANTIMICROBIAL THERAPEUTICS MARKET
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11.ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Drug Class
11.3.1.1. Antibacterial
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2.Market Share (%) 2024-2034F
11.3.1.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Antivirals
11.3.1.2.1.By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Antifungal
11.3.1.3.1.By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.4.Antiparasitic
11.3.1.4.1.By Value (USD Million) 2024-2034F
11.3.1.4.2. Market Share (%) 2024-2034F
11.3.1.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1.Oral
11.3.2.1.1.By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Tropic
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2.Market Share (%) 2024-2034F
11.3.2.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Injectable
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2.Market Share (%) 2024-2034F
11.3.2.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.4. Others
11.3.2.4.1. By Value (USD Million) 2024-2034F
11.3.2.4.2.Market Share (%) 2024-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3. By Disease Indication
11.3.3.1.Respiratory Infections
11.3.3.1.1.By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Urinary Tract Infections
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2.Market Share (%) 2024-2034F
11.3.3.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Skin and Soft Tissue Infections
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2.Market Share (%) 2024-2034F
11.3.3.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Sexually Transmitted Infections
11.3.3.4.1. By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Gastrointestinal Infections
11.3.3.5.1. By Value (USD Million) 2024-2034F
11.3.3.5.2.Market Share (%) 2024-2034F
11.3.3.5.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.6. Central Nervous System Infections
11.3.3.6.1. By Value (USD Million) 2024-2034F
11.3.3.6.2.Market Share (%) 2024-2034F
11.3.3.6.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.7. Others
11.3.3.7.1. By Value (USD Million) 2024-2034F
11.3.3.7.2.Market Share (%) 2024-2034F
11.3.3.7.3.Y-o-Y Growth (%) 2024-2034F
12. NORTH AMERICA ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Class
12.3.2.By Route of Administration
12.3.3.By Disease Indication
12.4. Country
12.4.1. United States
12.4.2.Canada
13. EUROPE ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Class
13.3.2.By Route of Administration
13.3.3.By Disease Indication
13.4. Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4. Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. ASIA-PACIFIC ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Class
14.3.2.By Route of Administration
14.3.3.By Disease Indication
14.4. Country
14.4.1. India
14.4.2.China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. MIDDLE EAST AND AFRICA ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Class
15.3.2.By Route of Administration
15.3.3.By Disease Indication
15.4. Country
15.4.1. Israel
15.4.2.GCC
15.4.3.North Africa
15.4.4. South Africa
15.4.5.Rest of Middle East and Africa
16. LATIN AMERICA ANTIMICROBIAL THERAPEUTICS MARKET SIZE & FORECAST 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Class
16.3.2.By Route of Administration
16.3.3.By Disease Indication
16.4. Country
16.4.1. Mexico
16.4.2.Brazil
16.4.3.Rest of Latin America
17. COMPETITIVE LANDSCAPE
17.1. Company market share, 2023
17.2.Key player overview
17.3. Key stakeholders
18. COMPANY PROFILES
18.1. Pfizer Inc.
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2.Merck & Co., Inc.
18.3.GlaxoSmithKline plc (GSK)
18.4.Johnson & Johnson
18.5.Novartis International AG
18.6.Sanofi S.A.
18.7.Roche Holding AG
18.8.AstraZeneca PLC
18.9.Bayer AG
18.10.AbbVie Inc.
18.11. Bristol Myers Squibb Company
18.12.Eli Lilly and Company
18.13.Astellas Pharma Inc.
18.14.Gilead Sciences, Inc.
18.15.Boehringer Ingelheim GmbH
18.16.Other Prominent Players
19. APPENDIX
20.CONSULTANT RECOMMENDATION
